NCDB Adds New Primary Sites, Quality Measures, Clinical Updates

The Commission on Cancer (CoC) National Cancer Database (NCDB) has added four new primary sites and four new quality measures, in addition to two clinical updates.

The new primary sites are as follows:

• Bladder
• Cervix
• Kidney
• Prostate

The new quality measures are as follows:

• BLCT1: For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy* is initiated within 24 hours of the procedure or recommended.

*chemotherapy within 24 hours of the transurethral resection assumed to be intravesical; however, the NCDB does not differentiate this from systemic chemotherapy.

• CBRRT: For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used.
• KPN: For patients with surgically managed cT1a kidney tumors, partial nephrectomy is performed.
• PTSRV: For patients with low-risk prostate cancer (Gleason <= 6 and PSA < 10 and <= cT2), active surveillance is performed.

The following quality measures are reflective of clinical updates:

• BneoCT: For patients <=75 years old with HER2+ or triple negative breast cancer with any clinical N > 0 or clinical T > 1, neoadjuvant chemotherapy and/or immunotherapy is initiated within 60 days of diagnosis, or recommended.
• RneoRT: For patients with surgically treated clinical T4NanyM0 or TanyN2M0 rectal cancer, neoadjuvant radiation therapy is initiated within 9 months prior to resection or recommended.